BRPI0514835A - variante de polipetìdeo de box de domìnio de ligação por alta afinidade de hmbg1 humano e/ou não humano ou de fragmento biologicamente ativo de box-a de hmgb1, molécula de ácido nucléico, uso, composição farmacêutica e dispositivo médico - Google Patents

variante de polipetìdeo de box de domìnio de ligação por alta afinidade de hmbg1 humano e/ou não humano ou de fragmento biologicamente ativo de box-a de hmgb1, molécula de ácido nucléico, uso, composição farmacêutica e dispositivo médico

Info

Publication number
BRPI0514835A
BRPI0514835A BRPI0514835-9A BRPI0514835A BRPI0514835A BR PI0514835 A BRPI0514835 A BR PI0514835A BR PI0514835 A BRPI0514835 A BR PI0514835A BR PI0514835 A BRPI0514835 A BR PI0514835A
Authority
BR
Brazil
Prior art keywords
human
box
hmgb1
biologically active
nucleic acid
Prior art date
Application number
BRPI0514835-9A
Other languages
English (en)
Inventor
Silvano Fumero
Luisa Bertarione Rava Rossa
Domenico G Barone
Lila Drittanti
Thierry Guyon
Gilles Borrelly
Barbara Canepa
Chiara Lorenzetto
Original Assignee
Creabilis Therapeutics Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creabilis Therapeutics Spa filed Critical Creabilis Therapeutics Spa
Publication of BRPI0514835A publication Critical patent/BRPI0514835A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)

Abstract

VARIANTE DE POLIPEPTìDEO DE BOX DE DOMìNIO DE LIGAçãO POR ALTA AFINIDADE DE HMBG1 HUMANO E/OU NãO HUMANO OU DE FRAGMENTO BIOLOGICAMENTE ATIVO DE BOX-A DE HMGB1, MOLéCULA DE áCIDO NUCLéICO, USO, COMPOSIçãO FARMACêUTICA E DISPOSITIVO MéDICO. Refere-se a variantes de polipeptídeo do Box-A de domínio de ligação de alta afinidade de HMGB-I (HMGB1 Box-A) ou a um fragmento biologicamente ativo de Box-A de HMGB1, que são obtidos através de mutações sistêmicas de aminoácidos simples da proteína de Box-A de HMGB-1 de tipo selvagem e que mostram uma resistência aumentada a proteases e que são, portanto, caracterizadas por perfis farmacocinéticos e farmacodinâmicos mais favoráveis. Além do mais, a presente invenção refere-se ao uso das ditas moléculas de polipeptídeo de Box-A de HMGB1 para diagnosticar, prevenir, aliviar e/ou tratar patologias associadas a HMGB1 extracelular.
BRPI0514835-9A 2004-09-03 2005-09-05 variante de polipetìdeo de box de domìnio de ligação por alta afinidade de hmbg1 humano e/ou não humano ou de fragmento biologicamente ativo de box-a de hmgb1, molécula de ácido nucléico, uso, composição farmacêutica e dispositivo médico BRPI0514835A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04425665 2004-09-03
IT2005009528 2005-09-05

Publications (1)

Publication Number Publication Date
BRPI0514835A true BRPI0514835A (pt) 2008-06-24

Family

ID=35768125

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514835-9A BRPI0514835A (pt) 2004-09-03 2005-09-05 variante de polipetìdeo de box de domìnio de ligação por alta afinidade de hmbg1 humano e/ou não humano ou de fragmento biologicamente ativo de box-a de hmgb1, molécula de ácido nucléico, uso, composição farmacêutica e dispositivo médico

Country Status (10)

Country Link
US (2) US7635679B2 (pt)
EP (1) EP1797118A2 (pt)
JP (1) JP5622351B2 (pt)
KR (1) KR101249287B1 (pt)
AU (1) AU2005279308B2 (pt)
BR (1) BRPI0514835A (pt)
CA (1) CA2579094C (pt)
MX (1) MX2007002557A (pt)
NZ (1) NZ553809A (pt)
WO (1) WO2006024547A2 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
WO2004022593A2 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
JP4792392B2 (ja) 2003-09-11 2011-10-12 コーナーストーン セラピューティクス インコーポレイテッド Ｈｍｇｂ１に対するモノクローナル抗体
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US20100040607A1 (en) * 2005-05-13 2010-02-18 Tracey Kevin J Combination Therapy with Inhibitors of HMGB and Caspase for the Treatment of Inflammatory Diseases
EP1909834A2 (en) * 2005-07-18 2008-04-16 Critical Therapeutics, Inc. Use of hmgb1 antagonists for the treatment of inflammatory skin conditions
EP2084274A2 (en) 2006-06-19 2009-08-05 Nautilus Technology LLC Modified coagulation factor ix polypeptides and use thereof for treatment
CN101563363B (zh) 2006-06-21 2013-01-02 南卡罗来纳医疗大学研究发展基金会 用于治疗疾病的靶向补体因子h
SI2068935T1 (sl) * 2006-09-15 2011-07-29 Creabilis Therapeutics S R L Polimerni konjugati od Box-A od HMGB1 in Box-A variante od HMGB1
MX2009002820A (es) * 2006-09-15 2009-06-04 Creabilis Therapeutics Spa Conjugados polimericos de box-a de hmgb1 y variantes de box-a de hmgb1.
JP5676253B2 (ja) 2008-04-30 2015-02-25 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
RS20120461A1 (en) 2009-07-02 2013-06-28 Musc Foundation For Research Development METHODS FOR STIMULATION OF LIVER REGENERATION
JP5746191B2 (ja) * 2009-10-19 2015-07-08 ハナル バイオファーマ カンパニーリミテッドＨａｎＡｌｌ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． 修飾されたヒト腫瘍壊死因子受容体−１ポリペプチドまたはその断片及びその製造方法
US11191786B2 (en) 2009-10-28 2021-12-07 StemRIM Inc. Agents for promoting tissue regeneration by recruiting bone marrow mesenchymal stem cells and/or pluripotent stem cells into blood
AU2010314931A1 (en) 2009-11-05 2012-06-21 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
JP5986990B2 (ja) 2010-05-14 2016-09-06 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 改善された補体レセプター２（ｃｒ２）ターゲティング基
WO2011163412A1 (en) 2010-06-22 2011-12-29 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the c3d fragment of complement component 3
US10272040B2 (en) 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
KR101279641B1 (ko) * 2011-01-05 2013-06-27 인하대학교 산학협력단 Ｈｉｈｐ－２를 유효성분으로 함유하는 신경보호용 조성물
CA2834255C (en) 2011-04-26 2021-11-02 Genomix Co., Ltd. Peptide for inducing regeneration of tissue and use thereof
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
WO2014065348A1 (ja) 2012-10-25 2014-05-01 株式会社ジェノミックス Hmgb1断片を利用した脊髄の損傷に対する新規治療法
CA2889275C (en) 2012-10-25 2021-06-15 Katsuto Tamai Novel method for treating cardiac infarction using hmgb1 fragment
US9956195B2 (en) * 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
GB201508337D0 (en) 2015-05-15 2015-06-24 Hmgbiotech S R L Novel peptides
RU2768186C2 (ru) 2015-12-11 2022-03-23 Рупрехт-Карлс-Университет Гейдельберг Комбинированные лекарственные средства, содержащие модуляторы pkm2 и hmgb1
CN110494154B (zh) 2017-01-27 2023-09-29 斯特姆里姆有限公司 心肌病、陈旧性心肌梗塞及慢性心力衰竭的治疗剂
MX2019012738A (es) * 2017-04-25 2020-02-07 Shionogi & Co Peptido para inducir la regeneracion de tejido, y uso del mismo.
WO2019107530A1 (ja) * 2017-12-01 2019-06-06 株式会社ステムリム 炎症性腸疾患の治療薬
CA3117107A1 (en) * 2018-10-25 2020-04-30 Osaka University Therapeutic agent for cartilage disorder
US11684653B2 (en) * 2019-03-06 2023-06-27 The Cleveland Clinic Foundation Compositions and method for reducing virulence of microorganisms
CN113151329B (zh) * 2021-03-30 2023-09-08 云南师范大学 中性蛋白酶突变体及其构造方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7754217B2 (en) * 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
SK15422003A3 (sk) * 2001-05-15 2005-01-03 Research Institute North Shore-Long Island Jewish Použitie fragmentov HMG ako protizápalových činidiel
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
WO2004000382A1 (en) * 2002-06-21 2003-12-31 Genzyme Corporation Silicone blends and composites for drug delivery
WO2004022747A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational directed protein evolution using two-dimensional rational mutagenesis scanning
PL376169A1 (en) * 2002-11-15 2005-12-27 Novartis Ag Drug delivery system
NZ540067A (en) * 2002-11-20 2007-05-31 Critical Therapeutics Inc A purified preparation of antibodies that specifically bind to a high mobility group box protein (HMGB) B box but do not specifically to non-B box epitopes of HMGB
JP2004222953A (ja) * 2003-01-22 2004-08-12 Kanegafuchi Chem Ind Co Ltd 生体留置用ステント
CH694905A5 (it) * 2003-03-25 2005-09-15 Marco Ostini Peptidi derivati dalla proteina HMGB1 per l'immunoterapia attiva nell'infiammazione sistematica letale.
WO2005025604A2 (en) * 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response

Also Published As

Publication number Publication date
KR20070059128A (ko) 2007-06-11
CA2579094C (en) 2014-12-02
WO2006024547A3 (en) 2006-06-01
US7635679B2 (en) 2009-12-22
EP1797118A2 (en) 2007-06-20
WO2006024547A2 (en) 2006-03-09
NZ553809A (en) 2010-03-26
US8058232B2 (en) 2011-11-15
CA2579094A1 (en) 2006-03-09
US20110052493A1 (en) 2011-03-03
MX2007002557A (es) 2007-10-10
AU2005279308A1 (en) 2006-03-09
KR101249287B1 (ko) 2013-04-01
AU2005279308B2 (en) 2012-05-03
US20080038309A1 (en) 2008-02-14
JP2008511300A (ja) 2008-04-17
JP5622351B2 (ja) 2014-11-12

Similar Documents

Publication Publication Date Title
BRPI0514835A (pt) variante de polipetìdeo de box de domìnio de ligação por alta afinidade de hmbg1 humano e/ou não humano ou de fragmento biologicamente ativo de box-a de hmgb1, molécula de ácido nucléico, uso, composição farmacêutica e dispositivo médico
DK2369005T3 (da) Biologisk aktive proteiner med forøget stabilitet in vivo og/eller in vitro
EA201001883A1 (ru) Мутанты fgf21 и их применение
WO2006052821A3 (en) Compositions and methods for treatment of protein misfolding and protein aggregation diseases
TNSN08064A1 (en) Albumin fusion proteins
CL2007003303A1 (es) Molecula de enlace para la proteina lingo-1; polinucleotido que la codifica; vector y celula que lo comprenden; composicion farmaceutica que comprende la molecula de enlace; y su uso para el tratamiento de lesiones del sistema nervioso central.
EA201990619A1 (ru) Fgf21 мутанты и их применение
CY1111411T1 (el) Αναλογα του παρομοιου-με-την-γλυκαγονη-πεπτιδιου-2(glp-2)
BRPI0714844B8 (pt) molécula de ácido nucleico e seus usos, composição farmaceutica e complexo
RU2014122609A (ru) Модифицированная константная область антитела
BRPI0816405B8 (pt) complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação
BRPI0507026A (pt) proteìnas de fusão de albumina
SE0400274D0 (sv) New polypeptide
ATE466886T1 (de) Adzyme und deren verwendungen
BR112012007374A2 (pt) composição, formulação oral, injetável, inalável ou nebulizável, e, ácido nucleico isolado ou recombinante
NO20043891L (no) Anti-A-beta-antistoffer og deres anvendelse
WO2008043822A3 (en) Amino acid sequences that bind to a desired molecule in a conditional manner
DE502005009389D1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
BRPI0616712B8 (pt) método para amidar polipeptídeos com terminais c de aminoácido básicos por meio de endoproteases específicas
DK1869071T3 (da) TNF-alfa-bindende polypeptid, anvendelser deraf og fremgangsmåder, der gør brug deraf
ATE517118T1 (de) Bis-met-histone
ATE520025T1 (de) Test für morbus-parkinson-therapeutika
BR122018077204B8 (pt) peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica
BRPI0409736A (pt) anticorpos monoclonais, variantes de polipeptìdeo stop-1, molécula de ácido nucléico, vetor, célula hospedeira, composições, métodos relativos e artigos industrializados
Lambert et al. Probing the transient interaction between the small heat-shock protein Hsp21 and a model substrate protein using crosslinking mass spectrometry

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL